In the trial, which included around 2,000 children, there were three COVID-19 cases among the group that received the vaccine and 16 cases in the placebo group. In the trial, twice as many children received the vaccine as the placebo.
Pfizer/BioNTech are seeking FDA emergency use authorization of a two-dose regimen of their 10-microgram dose for children ages 5 to 11. The two doses would be administered three weeks apart. Last month, Pfizer released details of a Phase 2/3 trial that showed its COVID-19 vaccine was safe and generated a"robust" antibody response in children ages 5 to 11. The trial included 2,268 participants ages 5 to 11. Participants' immune responses were measured by looking at neutralizing antibody levels in their blood and comparing those levels to a control group of 16- to 25-year-olds who were given a two-dose regimen with the larger 30-microgram dose.
The FDA's Vaccines and Related Biological Products Advisory Committee is scheduled to meet October 26 to discuss whether to recommend the vaccine for authorization for those ages 5 to 11. If authorized, this would be the first COVID-19 vaccine for younger children. The Pfizer/BioNTech vaccine is approved for people age 16 and older and has an EUA for people ages 12 to 15.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNN Philippines - 🏆 13. / 63 Read more »
Source: ABSCBNNews - 🏆 5. / 83 Read more »
Source: CNN Philippines - 🏆 13. / 63 Read more »
Source: ABSCBNNews - 🏆 5. / 83 Read more »
Source: CNN Philippines - 🏆 13. / 63 Read more »
Source: CNN Philippines - 🏆 13. / 63 Read more »